文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

COAPT试验:经导管二尖瓣修复对比药物治疗在心衰合并继发性二尖瓣反流中的成本效益

Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial.
PubMed 文献 · Circulation · 2019-09-29

基于COAPT试验的患者层面经济学分析,评估经导管二尖瓣修复(TMVr)联合指南导向药物治疗(GDMT)对比单纯GDMT用于心衰合并3-4+继发性二尖瓣反流患者的成本效益。TMVr初始费用较高,但随访费用较低;

要点

  • TMVr联合GDMT较单纯GDMT增加预期寿命1.13年和质量调整生命年0.82年。
  • TMVr初始手术及住院费用较高,但随访期间医疗费用显著低于GDMT。

核心结论

  • 对于有症状的心衰合并3-4+继发性二尖瓣反流患者,TMVr较GDMT增加预期寿命和质量调整预期寿命,增量成本效益比符合美国现行经济价值阈值。

研究设计与样本

  • 基于COAPT试验数据的前瞻性患者层面经济学分析,从美国医疗系统角度比较TMVr+GDMT与单纯GDMT。
  • COAPT试验纳入心衰合并3-4+继发性二尖瓣反流患者,随机接受TMVr+GDMT或GDMT。
  • 使用Short Form Six-Dimension健康调查在基线及1、6、12、24个月评估健康效用。

关键数值与推荐

  • COAPT试验纳入心衰合并3至4+继发性二尖瓣反流患者。
  • TMVr使用MitraClip行缘对缘修复。
  • GDMT为最大耐受的指南导向药物治疗。
  • 增量成本效益比阈值参考美国现行经济价值标准(原文未给出具体阈值数值)。

临床怎么用

  • 对于心衰合并3-4+继发性二尖瓣反流且有症状的患者,TMVr联合GDMT在经济上可接受。
  • TMVr初始费用较高,但随访期间可降低医疗资源使用费用。
  • 临床决策可结合患者预期寿命和生活质量改善权衡TMVr的增量成本。

局限性

  • 分析基于COAPT试验数据,外推至其他人群需谨慎。
  • 成本估算基于美国医疗系统,其他国家适用性有限。
  • 终生模型依赖试验内生存、效用和费用数据外推,存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted in reduced mortality and heart failure hospitalizations and improved quality of life compared with maximally tolerated guideline-directed medical therapy (GDMT) in patients with heart failure and 3 to 4+ secondary mitral regurgitation. Whether TMVr is cost-effective compared with GDMT in this population is unknown. METHODS: We used data from the COAPT trial to perform a formal patient-level economic analysis of TMVr+GDMT versus GDMT alone for patients with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US healthcare system. Costs for the index TMVr hospitalization were assessed using a combination of resource-based accounting and hospital billing data (when available). Follow-up medical care costs were estimated on the basis of medical resource use collected during the COAPT trial. Health utilities were estimated for all patients at baseline and 1, 6, 12, and 24 months with the Short Form Six-Dimension Health Survey. RESULTS: Initial costs for the TMVr procedure and index hospitalization were $35 755 and $48 198, respectively. Although follow-up costs were significantly lower with TMVr compared with GDMT ($26 654 versus $38 345; P=0.018), cumulative 2-year costs remained higher with TMVr because of the upfront cost of the index procedure ($73 416 versus $38 345; P<0.001). When in-trial survival, health utilities, and costs were modeled over a lifetime horizon, TMVr was projected to increase life expectancy by 1.13 years and quality-adjusted life-years by 0.82 years at a cost of $45 648, yielding a lifetime incremental cost-effectiveness ratio of $40 361 per life-year gained and $55 600 per quality-adjusted life-year gained. CONCLUSIONS: For symptomatic patients with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and quality-adjusted life expectancy compared with GDMT at an incremental cost per quality-adjusted life-year gained that represents acceptable economic value according to current US thresholds. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01626079.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Baron SJ, Wang K, Arnold SV, et al. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial. Circulation. 2019. PMID: 31564137. doi:10.1161/CIRCULATIONAHA.119.043275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。